Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | CA12 | O43570 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | CA9 | Q16790 | 4/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2606325 | 0.89 | ALOX15 (0.32) | ALOX15ALOX12KCNH2TRPV1 | |
| SCHEMBL2570841 | 0.87 | ALOX15 (0.44) | ALOX15ALOX12MAPTMEN1KMT2A | |
| SCHEMBL245775 | 0.85 | ALOX15 (0.31) | ALOX15ALOX12 | |
| SCHEMBL24103983 | 0.82 | PREP (0.33) | ALOX15ALOX12PREP | |
| SCHEMBL10042945 | 0.82 | ALOX12 (0.42) | ALOX15ALOX12MAPTMEN1KMT2A | |
| SCHEMBL2570060 | 0.81 | ALOX15 (0.44) | ALOX15ALOX12KMT2ACYP19A1KCNH2 | |
| SCHEMBL12052438 | 0.81 | ALOX12 (0.41) | ALOX15ALOX12MAPTMEN1KMT2A | |
| SCHEMBL2570756 | 0.78 | MEN1 (0.47) | ALOX15ALOX12MAPTMEN1KMT2A | |
| SCHEMBL4559222 | 0.77 | BACE1 (0.31) | ALDH1A1 | |
| SCHEMBL12063383 | 0.76 | ALDH1A1 (0.33) | ALOX15ALOX12MAPTKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-05-19 | — | — | US | disclosed |
| EP-2436680-B1 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9198895-B2 | Chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150238458-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-08-27 | — | — | US | disclosed |
| US-8957109-B2 | Chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20140161908-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-1809618-B1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8461361-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-8163795-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120004296-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC (US) | 2012-01-05 | — | — | US | disclosed |
| US-8080675-B2 | Chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20060074126-A1 | Chroman derivatives, medicaments and use in therapy | NOVOGEN RESEARCH PTY LTD | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238458-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 3665/4885ALOX12 3724/4885MAPT 2679/4885 |
| US-20160136129-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 3665/4885ALOX12 3724/4885MAPT 2679/4885 |
| US-20120172424-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 3665/4885ALOX12 3724/4885MAPT 2679/4885 |
| US-20140161908-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 4133/4885ALOX12 4083/4885MAPT 1677/4885 |
| US-20060074126-A1 | Chroman derivatives, medicaments and use in therapy | CDYL, XPA, TP53 | ALOX15 3665/4885ALOX12 3724/4885MAPT 2679/4885 |
| US-20120004296-A1 | CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ALOX15 3665/4885ALOX12 3724/4885MAPT 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.